logo

Eidos Therapeutics, Inc. (EIDX)



Trade EIDX now with
  Date
  Headline
4/15/2019 8:39:25 AM Eidos Therapeutics Q4 Net Loss Attributable $9.9 Mln Or $0.27 Per Share
2/27/2019 7:10:05 AM Eidos Therapeutics Begins ATTRibute-CM, A Phase 3 Study Of AG10 In ATTR-CM With Registrational 12-month Endpoint
12/6/2018 4:20:43 PM Eidos Therapeutics Appoints William Lis To Board Of Directors
10/26/2018 8:07:23 AM Eidos Therapeutics Gets Positive Opinion For Orphan Designation From The European Medicines Agency For AG10
10/5/2018 9:12:02 AM Eidos Therapeutics To Present Phase 2 Data For AG10 In TTR Amyloidosis Cardiomyopathy
9/17/2018 8:16:40 AM Eidos Therapeutics Presents Data From Phase 1 Clinical Trial Of AG10 At The 22nd Annual Scientific Meeting Of HFSA